TESARO (NASDAQ:TSRO) Rating Reiterated by HC Wainwright

TESARO (NASDAQ:TSRO)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Monday, November 20th. They currently have a $158.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 89.61% from the company’s current price.

A number of other equities analysts have also recently weighed in on TSRO. Robert W. Baird restated a “neutral” rating and set a $140.00 price objective (down from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Jefferies Group set a $124.00 target price on shares of TESARO and gave the stock a “hold” rating in a report on Thursday, August 17th. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 target price on shares of TESARO in a report on Thursday, August 10th. Credit Suisse Group set a $190.00 target price on shares of TESARO and gave the stock a “buy” rating in a report on Friday, August 18th. Finally, BidaskClub raised shares of TESARO from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. TESARO has a consensus rating of “Buy” and an average price target of $159.39.

TESARO (NASDAQ:TSRO) traded down $1.43 during trading hours on Monday, reaching $83.33. 518,083 shares of the company’s stock traded hands, compared to its average volume of 1,017,733. TESARO has a 12 month low of $79.03 and a 12 month high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.

TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm had revenue of $142.77 million during the quarter, compared to analysts’ expectations of $130.57 million. During the same period in the previous year, the business posted ($1.72) EPS. The business’s revenue was up 740.3% compared to the same quarter last year. equities research analysts expect that TESARO will post -8.17 earnings per share for the current year.

In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the transaction, the senior vice president now directly owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James O. Armitage sold 10,000 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $1,171,300. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,421 shares of company stock worth $1,312,175. 40.50% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in TSRO. Exane Derivatives purchased a new position in TESARO in the 3rd quarter valued at $106,000. Botty Investors LLC purchased a new position in TESARO in the 2nd quarter valued at $140,000. Nordea Investment Management AB purchased a new position in TESARO in the 2nd quarter valued at $167,000. Oppenheimer Asset Management Inc. grew its position in TESARO by 3,042.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the last quarter. Finally, Toronto Dominion Bank grew its position in TESARO by 244.6% in the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “TESARO (NASDAQ:TSRO) Rating Reiterated by HC Wainwright” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/07/tesaro-inc-tsro-stock-rating-reaffirmed-by-hc-wainwright-updated-updated.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply